DBV Technologies Files 2024 Half-Year Report Access Details

DBV Technologies has officially filed its Half-Year Report for the first semester of 2024 with the French market authority, Autorité des Marchés Financiers (AMF). This report, which includes detailed financial and operational data for the period ending June 30, 2024, is now accessible to the public. Interested parties can view or download the report from DBV Technologies' website in the Investors/Financial Information section or directly from the AMF website, though it is available only in French. Additionally, the report can be obtained free of charge by mail or email upon request.

DBV Technologies, a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatment options for food allergies and other immunologic conditions. The company's primary focus is on leveraging its proprietary technology platform, Viaskin™, to tackle food allergies. Food allergies affect millions of people, including a significant number of young children, and can range from mild symptoms to severe, life-threatening anaphylaxis.

Viaskin™ employs a method known as epicutaneous immunotherapy (EPIT™), which introduces microgram amounts of an allergen to the immune system through intact skin. This non-invasive treatment aims to re-educate and desensitize the immune system to allergens by taking advantage of the skin's immune tolerizing properties. DBV Technologies is committed to transforming the management of food allergies through this innovative approach.

The company's flagship product, Viaskin Peanut, is currently undergoing clinical trials aimed at peanut-allergic toddlers (ages 1 through 3) and children (ages 4 through 7). These trials are critical in assessing the safety and efficacy of the Viaskin platform, with the ultimate goal of providing an effective treatment for peanut allergies.

Headquartered in Châtillon, France, DBV Technologies also operates in North America, with offices in Warren, New Jersey. The company’s ordinary shares are listed on Euronext Paris under the ticker symbol DBV and the ISIN code FR0010417345. Additionally, its American Depositary Shares (ADSs), each representing one ordinary share, are traded on the Nasdaq Stock Market under the ticker symbol DBVT. For more information, the public is encouraged to visit DBV Technologies' official website and follow the company on social media platforms such as X (formerly Twitter) and LinkedIn.

DBV Technologies continues to lead the way in addressing significant unmet medical needs in the field of food allergies through innovative research and development. The company’s commitment to transforming the lives of those affected by food allergies remains steadfast, as evidenced by its ongoing clinical programs and proactive engagement with both the medical community and the public.

Viaskin and EPIT are registered trademarks of DBV Technologies, underscoring the proprietary nature of these groundbreaking treatment methods. As the company progresses with its clinical trials and regulatory filings, it continues to keep stakeholders informed through regular updates and transparent communication.